methyl{2-[(5-nitro(pyridin-2-yl))amino]ethyl}amine | 345629-42-7

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: methyl{2-[(5-nitro(pyridin-2-yl))amino]ethyl}amine
• 英文别名: 2-(methylaminoethyl)(5-nitro(2-pyridyl))amine；N~1~-Methyl-N~2~-(5-nitropyridin-2-yl)ethane-1,2-diamine；N-methyl-N'-(5-nitropyridin-2-yl)ethane-1,2-diamine
• CAS: 345629-42-7
• 化学式: C₈H₁₂N₄O₂
• 分子量: 196.209
• InChiKey: NXONIPCBEYLWBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  82.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl{2-[(5-nitro(pyridin-2-yl))amino]ethyl}amine 、 2-(2,4-dichlorophenyl)-4-fluoro-1-nitrobenzene 在 N,N-二异丙基乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 生成 N-(2',4'-dichloro-6-nitro-1,1'-biphenyl-3-yl)-N-methyl-N'-(5-nitropyridin-2-yl)ethane-1,2-diamine
  参考文献：
  名称：

  [EN] INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3
  [FR] INHIBITEURS DE GLYCOGENE SYNTHASE KINASE 3

  摘要：

  提供了化学式(I)的新碳环化合物，以及在体外抑制糖原合成酶激酶（GSK3）活性和在体内治疗GSK3介导的疾病的方法、组合物。本发明的方法、化合物和组合物可单独使用，或与其他药理活性剂结合在一起，用于治疗由GSK3活性介导的疾病，例如糖尿病、阿尔茨海默病、其他神经退行性疾病（如帕金森病和亨廷顿病）、肥胖、动脉粥样硬化心血管疾病、原发性高血压、多囊卵巢综合征、X综合征、缺血、创伤性脑损伤、躁郁症、免疫功能缺陷或癌症。

  公开号：

  WO2004037791A1

文献信息

• Dihydropyrancarboxamides and uses thereof
  申请人：Schreiber L. Stuart

  公开号：US20080070916A1

  公开（公告）日：2008-03-20

  The present invention provides novel dihydropyrancarboxamide compounds of formula (I): and collections of these compounds, and provides methods for the synthesis of these compounds; wherein R 1 -R 6 are as defined herein. Additionally, the present invention provides pharmaceutical compositions and methods for treating disorders such as proliferative diseases, and cancer, to name a few.

  本发明提供了式（I）的新型二氢吡嗪羧酰胺化合物以及这些化合物的集合，并提供了合成这些化合物的方法；其中R1-R6如本文所定义。此外，本发明还提供了治疗增生性疾病和癌症等疾病的药物组合物和方法。
• PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION
  申请人：NADLER Jerry L.

  公开号：US20080300189A1

  公开（公告）日：2008-12-04

  Pharmaceutical compositions and methods for using are provided for restoring β-cell mass and function in a mammal in need thereof. The pharmaceutical compositions have a biological response modifier and a β-cell growth factor in admixture with a pharmaceutically acceptable carrier, adjuvant or vehicle.
• ENCAPSULATION SYSTEM
  申请人：Nadler Jerry L.

  公开号：US20090269313A1

  公开（公告）日：2009-10-29

  An encapsulation system for use in the treatment of diabetes (Types 1 or 2, and LADA) are provided. The system has (1) a delivery vehicle comprising a selectively permeable membrane that allows passage of glucose, insulin and other nutrients through the membrane, but prevents large molecules such as antibodies or inflammatory cells from passing through the membrane; (2) a population of islet cells or insulin producing cells encapsulated by said membrane; and (3) a biological response modifier that may be in contact with the membrane or encapsulated by the membrane. Generally, the biological response modifier is a compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the following formula: wherein: X, Y and Z are independently selected from a member of the group consisting of C(R 3 ), N, N(R 3 ) and S; R 1 is selected from a member of the group consisting of hydrogen, methyl, C (5-9) alkyl, C (5-9) alkenyl, C (5-9) alkynyl, C (5-9) hydroxyalkyl, C (3-8) alkoxyl, C (5-9) alkoxyalkyl, the R 1 being optionally substituted; R 2 and R 3 are independently selected from a member of the group consisting of hydrogen, halo, oxo, C (1-20) alkyl, C (1-20) hydroxyalkyl, C (1-20) thioalkyl, C (1-20) alkylamino, C (1-20) alkylaminoalkyl, C (1-20) aminoalkyl, C (1-20) aminoalkoxyalkenyl, C (1-20) aminoalkoxyalkynyl, C (1-20) diaminoalkyl, C (1-20) triaminoalkyl, C (1-20) tetraaminoalkyl, C (5-15) aminotrialkoxyamino, C (1-20) alkylamido, C (1-20) alkylamidoalkyl, C (1-20) amidoalkyl, C (1-20) acetamidoalkyl, C (1-20) alkenyl, C (1-20) alkynyl, C (3-8) alkoxyl, C (1-11) alkoxyalkyl, and C (1-20) dialkoxyalkyl.
• US7186709B2
  申请人：——

  公开号：US7186709B2

  公开（公告）日：2007-03-06
• US7393827B2
  申请人：——

  公开号：US7393827B2

  公开（公告）日：2008-07-01